← 返回

中低收入国家的 CAR-T 细胞治疗:talicabtagene autoleucel 在印度获批

英文原题:CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India.

查看英文原题

CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India.

PubMed 2025/03/13(内容时间) Lancet Haematol Q1 · IF 20.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

摘要

这条来源本身就没有摘要(PubMed 未提供),不是「还没翻译」。可以点最下面的「在 PubMed 查看」打开原文献页面。

论文信息

作者
Paruzzo L、Ruella M
第一作者单位
Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.United States
通讯作者单位
Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: mruella@upenn.edu.United States
文献类型
评论
期刊
The Lancet. Haematology2025 Apr
原文标识
PubMed 40090349 · DOI 10.1016/S2352-3026(25)00040-7